文献速递妇科

胰高血糖素样肽-1受体激动剂与卵巢癌生存的关联:一项基于人群的队列研究

Association between glucagon-like peptide-1 receptor agonists and ovarian cancer survival: A population-based cohort study.
PubMed 文献 · Gynecol Oncol · 2025-06-18

基于TriNetX全球健康记录网络的回顾性队列研究,纳入2014至2023年诊断为卵巢癌的女性患者,按GLP-1RA暴露分组并进行1:1倾向评分匹配,每组1023例。GLP-1RA使用者全因死亡率显著低于非使用者(7.94% vs 19.71%;HR 0.45;95%CI 0.35-0.59;log-rank P<0.001)。作者认为GLP-1RA可能是有前景的辅助策略,需进一步前瞻性研究。

要点

  • 匹配后每组1023例,GLP-1RA使用者全因死亡率7.94%,非使用者19.71%。
  • GLP-1RA使用与全因死亡风险降低相关(HR 0.45;95%CI 0.35-0.59;P<0.001)。
  • 合并心力衰竭或慢性肾脏病的患者中未观察到显著获益。

核心结论

  • GLP-1RA使用与卵巢癌女性总生存期显著改善相关。
  • 鉴于其广泛临床使用和良好安全性,GLP-1RA可能是有前景的辅助策略,尤其适用于合并代谢紊乱者。
  • 作者认为需进一步前瞻性研究。

研究设计与样本

  • 回顾性队列研究,使用TriNetX全球健康记录网络。
  • 纳入2014至2023年诊断为卵巢癌的女性患者。
  • 按GLP-1RA暴露分为两组,进行1:1倾向评分匹配以平衡人口学、合并症、用药和癌症分期。
  • 匹配后每组1023例。
  • 采用Kaplan-Meier生存曲线和Cox比例风险模型估计总生存期,并进行亚组和敏感性分析。

主要发现

  • GLP-1RA使用者全因死亡率7.94%,非使用者19.71%(HR 0.45;95%CI 0.35-0.59;log-rank P<0.001)。
  • 生存获益在多数亚组中一致,包括接受化疗或PARP抑制剂的患者。
  • 合并心力衰竭或慢性肾脏病的患者中未观察到显著获益。
  • 敏感性分析支持主要分析结果。

临床怎么用

  • 作者认为GLP-1RA可能是有前景的辅助策略,尤其适用于合并代谢紊乱的卵巢癌女性。

局限性

  • 作者认为需进一步前瞻性研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the association between glucagon-like peptide-1 receptor agonist (GLP-1RA) use and all-cause mortality in women with ovarian cancer, using real-world data from a global federated health database. METHODS: We conducted a retrospective cohort study using the TriNetX global health records network. Female patients diagnosed with ovarian cancer between 2014 and 2023 were included. Patients were divided into two cohorts based on GLP-1RA exposure. A 1:1 propensity score matching was performed to balance demographics, comorbidities, medications, and cancer stage. Kaplan-Meier survival curves and Cox proportional hazards models were used to estimate overall survival. Subgroup and sensitivity analyses were performed. RESULTS: After matching, 1023 patients were included in each group. GLP-1RA users had a significantly lower all-cause mortality rate compared with non-users (7.94 % vs. 19.71 %; hazard ratio [HR], 0.45; 95 % confidence intervals [CI], 0.35-0.59; log-rank P < 0.001). The survival benefit was consistent across most subgroups, including patients receiving chemotherapy or Poly(ADP-ribose) polymerase (PARP) inhibitors. No significant benefit was observed in patients with heart failure or chronic kidney disease. Sensitivity analysis supports the primary analysis. CONCLUSIONS: Use of GLP-1RA was associated with substantially improved overall survival in women with ovarian cancer. Given their widespread clinical use and favorable safety profile, GLP-1RA may represent a promising adjunctive strategy for improving outcomes in women with ovarian cancer, particularly those with coexisting metabolic disorders. Further prospective studies are warranted.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Wang M, Dong T, Lucero M, et al. Association between glucagon-like peptide-1 receptor agonists and ovarian cancer survival: A population-based cohort study. Gynecol Oncol. 2025. PMID: 40554181. doi:10.1016/j.ygyno.2025.06.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。